C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 401/02 (2006.01) A61K 31/44 (2006.01)
Patent
CA 2439952
Compounds of formula (I) are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell- adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS- related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.
Selon l'invention, les composés de formule (I) constituent des antagonistes de VLA-4 et/ou d'alpha4/bêta7, et sont donc utiles dans l'inhibition ou la prévention de l'adhésion cellulaire et des pathologies induites par l'adhésion cellulaire. Ces composés peuvent être préparés en compositions pharmaceutiques et utilisés pour traiter le syndrome démentiel lié au sida, la conjonctivite allergique, la rhinite allergique, la maladie d'Alzheimer, l'asthme, l'athérosclérose, les symptômes associés à la transplantation autologue de moelle osseuse, certains types de néphrites toxiques et immunitaires, l'hypersensibilité cutanée de contact, la maladie intestinale inflammatoire, y compris la rectocolite hémorragique et la maladie de Crohn, les maladies pulmonaires inflammatoires, les séquelles inflammatoires d'infections virales, la méningite, la sclérose en plaques, le myélome multiple, la myocardite, les symptômes associés à la transplantation d'organes, le psoriasis, la fibrose pulmonaire, la resténose, la rétinite, l'arthrite rhumatoïde, l'arthrite septique, l'accident vasculaire cérébral, la métastase tumorale, l'uvéite et le diabète de type I.
Chang Linda L.
Doherty George
Hagmann William K.
Kamenecka Theodore M.
Lin Linus S.
Merck & Co. Inc.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Substituted n-arylsulfonyl-proline derivatives as potent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted n-arylsulfonyl-proline derivatives as potent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted n-arylsulfonyl-proline derivatives as potent... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1521379